Eupraxia Pharmaceuticals
A company focused on the development of locally delivered, extended-release alternatives to currently approved drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | CAD44.5m | Private Placement non VC |
| Total Funding | 000k | ||
| CAD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (130 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing precision therapeutics. The company leverages proprietary and innovative delivery technology to ensure the right dose of a drug is delivered to the right place for the right amount of time. This approach is particularly beneficial for indications with high unmet medical needs, where traditional drug delivery methods may fall short.
Eupraxia operates in the biotechnology and pharmaceutical markets, primarily serving healthcare providers and patients who require advanced therapeutic solutions. The company's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary drug delivery systems. Revenue is generated through partnerships, licensing agreements, and future product sales once regulatory approvals are obtained.
The company is led by a team of experienced life science professionals, including former executives from major financial institutions and healthcare companies. Their expertise helps drive the company's mission to improve patient outcomes through innovative medical solutions.
Keywords: precision therapeutics, drug delivery, biotechnology, clinical-stage, high unmet needs, proprietary technology, healthcare, pharmaceuticals, life sciences, innovation.